Skip Navigation



NDT Advance Access published online on August 25, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp415
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ni, J.
Right arrow Articles by Devuyst, O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ni, J.
Right arrow Articles by Devuyst, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009].
Published by Oxford University Press [on behalf of the ERA-EDTA]. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use distribution, and reproduction in any medium, provided the original work is properly cited.


Nitric oxide synthase isoforms play distinct roles during acute peritonitis

Jie Ni1, Rachel M. McLoughlin2, Alexandre Brodovitch1, Pierre Moulin1, Peter Brouckaert3, Barbara Casadei4, Olivier Feron1, Nicholas Topley2, Jean-Luc. Balligand1 and Olivier Devuyst1

1 Université catholique de Louvain Medical School, Brussels, Belgium 2 School of Medicine, Cardiff University, Cardiff, UK 3 Department for Molecular Biomedical Research, VIB and Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium 4 University Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK

Correspondence and offprint requests to: Olivier Devuyst; E-mail: olivier.devuyst{at}uclouvain.be



   Abstract
Top
 Abstract
Introduction
 Material and methods
 Results
 Discussion
 References
 
Background. Acute peritonitis is the most frequent complication of peritoneal dialysis (PD). Increased nitric oxide (NO) release by NO synthase (NOS) isoforms has been implicated in acute peritonitis, but the role played by the NOS isoforms expressed in the peritoneum is unknown.

Methods. We investigated the structural and functional consequences of acute peritonitis induced by LPS in wild-type (WT) mice versus knockout mice (KO) for the endothelial NOS (eNOS), the inducible NOS (iNOS) or the neuronal NOS (nNOS).

Results. The level of NO metabolites (NOx) in the dialysate was maximal 18 h after LPS injection. LPS induced a significant increase in the transport of small solutes and decreased ultrafiltration in WT mice. These changes, which occurred without vascular proliferation, were paralleled by the upregulation of nNOS and eNOS, and the induction of iNOS. The transport modifications induced by LPS were significantly reversed in eNOS KO mice, but not modified in mice lacking iNOS or nNOS. In contrast, the increase of dialysate NOx was abolished in iNOS KO mice and significantly reduced in eNOS KO mice, but left unchanged in mice lacking nNOS. Mice lacking iNOS also showed more severe inflammatory changes, and a trend towards increased mortality following LPS.

Conclusion. These data demonstrate specific roles for NOS isoforms in the peritoneal membrane and suggest that selective eNOS inhibition may improve peritoneal transport during acute peritonitis.

Keywords: acute peritonitis; knockout mice; LPS; NO synthases; peritoneal dialysis



   Introduction
Top
 Abstract
 Introduction
Material and methods
 Results
 Discussion
 References
 
Nitric oxide (NO) plays an essential role in a variety of processes including regulation of blood flow and vascular permeability, mucosal defence, leukocyte recruitment, immune regulation and neurotransmission. Three distinct NO synthase (NOS) isoforms are involved in the synthesis of NO from L-arginine. The neuronal (nNOS, NOS1) and endothelial (eNOS, NOS3) NOS are constitutive, calcium-dependent isoforms. nNOS, which was first located in the central and peripheral nervous system, is also detected in non-neuronal cells, including myocytes, epithelial cells, mast cells and neutrophils [1–4]. eNOS, first and foremost identified in endothelial cells, is also expressed in epithelial cells, smooth muscle cells and T lymphocytes [5–7]. The calcium-independent, inducible isoform (iNOS, NOS2) is expressed in many cell types, including macrophages and endothelial cells, and is induced by inflammatory cytokines and bacterial metabolites such as lipopolysaccharide (LPS) [8].

Acute peritonitis remains the most frequent complication of peritoneal dialysis (PD) [9]. Early studies by Krediet and colleagues have shown increased NO levels in the dialysate during acute peritonitis [10,11], which prompted us to investigate the molecular basis of the production of NO in the peritoneum. We first demonstrated specific NOS activity in the peritoneal membrane, due to the expression of the three NOS isoforms [12,13]. Under baseline conditions, eNOS is the predominant NOS isoform in the peritoneum, reflecting the endothelial component of the membrane. During acute peritonitis, there is a selective upregulation of both endothelial and inducible NOS isoforms, in parallel with structural modifications that include increased endothelial area and mononuclear cell infiltrate [10,12].

The role played by NO during peritonitis has been investigated in rat and mouse models using a 6-day model of catheter-induced peritonitis [14,15]. In this model, acute peritonitis was reflected by functional modifications, including increased transport for small solutes, faster glucose reabsorption and loss of ultrafiltration (UF), which were attributed to increased effective peritoneal surface area (EPSA) due to capillary recruitment and/or vascular proliferation [10,12]. Pharmacological studies with the non-specific NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) [14] as well as studies using eNOS knockout (KO) mice [15] demonstrated that the eNOS-derived NO was instrumental in the structural (vascular proliferation) and functional (hyperpermeability) modifications induced by acute peritonitis. However, these studies did not address the potential role(s) of other NOS isoforms in the peritoneal membrane and could not discriminate between the structural and functional effects in the early phase of acute peritonitis—when vascular proliferation has not yet occurred. Recent studies, based on the effect of L-NAME in a LPS-induced peritonitis mouse model [16], suggested that NO could play a role in the modifications of transport parameters in the early phase of peritonitis, in the absence of vascular proliferation. However, the latter investigation, performed in wild-type mice, could not address the contributions of the three different NOS isoforms in transport and structural changes in the peritoneum.

In the present study, we have used transgenic mouse models to provide direct evidence for a specific role of each NOS isoform in the functional changes and release of NO metabolites associated with acute peritonitis induced by LPS.



   Material and methods
Top
 Abstract
 Introduction
 Material and methods
Results
 Discussion
 References
 
Animals, experimental groups and acute peritonitis model
Experiments were performed on adult male C57 BL/6J mice (Iffa Credo, Brussels, Belgium) and eNOS, iNOS and nNOS mice (all on the C57BL/6J background). Mice lacking eNOS (eNOS KO) and their wild-type littermates (eNOS WT) were generated as described previously [17] and obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The iNOS WT and KO mice [18] were obtained from P. Brouckaert (Ghent University, Ghent, Belgium). The nNOS KO and WT mice [19] were obtained from B. Casadei (University of Oxford, Oxford, UK). All animals had access to appropriate standard diet and tap water ad libitum. The experiments were approved by the local Ethics Committee and conducted in accord with the NIH Guide for the Care and Use of Laboratory Animals.

The first series of experiments were performed on C57 BL/6J mice, including the LPS time-course study (n = 24 mice) and the investigation of transport parameters and structural changes at baseline and following LPS treatment (n = 14 pairs of mice). In a second round of experiments, at least six pairs of eNOS mice, iNOS mice and nNOS mice were investigated during LPS-induced acute peritonitis, in comparison with WT mice under control conditions. Acute peritonitis was generated by i.p. injection of LPS (10 mg/kg, Escherichia coli serotype O111: B4, Sigma). Eighteen hours after LPS injection, all mice underwent a peritoneal equilibration test (PET) as described below.

Peritoneal transport studies, tissue sampling
A peritoneal equilibration test (PET) was used to investigate peritoneal transport parameters in mice as previously described [20]. Briefly, after anaesthesia with ketamine and xylazine, mice were placed on a thermopad at 37°C and catheterized for blood pressure monitoring (right common carotid artery) and saline infusion (right jugular vein, 0.9% NaCl, 0.3 mL/ h). After 30 min, a silicon catheter (Venflon 22 GA, Baxter) was inserted into the peritoneal cavity and 2.0 mL of 7% dialysate (Dianeal; Baxter) was instilled [20]. Blood and dialysate samples (50–100 µL) were taken from carotid artery and the PD catheter at time 0 and at 30 min, 60 min, and 120 min of dwell time. Haematocrit was measured before PD exchange. At the end of the dwell, the dialysate was recovered from the peritoneal cavity and net UF was calculated [15,20]. Dialysate white blood cells (WBCs) were counted using a haemocytometer (Marienfeld, Lauda, Germany) and the differential count (macrophages, neutrophils and lymphocytes) was established after Wright-Giemsa staining (Sigma) following the manufacturer's instruction. The mice were exsanguined and urea, glucose, sodium and total protein were assayed using Kodak Ektachem DT60 II and DTE II analysers (Eastman Kodak Company, Rochester, NY, USA). Peritoneum samples were carefully dissected and processed for fixation and protein extraction as described previously [12–15]. Samples from the visceral and parietal peritoneum were fixed for 3 h at 4°C in 4% paraformaldehyde in a 0.1 M phosphate buffer, rinsed and embedded in paraffin. Samples from the visceral peritoneum were dissected, snap-frozen in liquid nitrogen and stored at –80°C.

Antibodies
The NOS isoforms were detected with well-characterized monoclonal antibodies against eNOS, nNOS and iNOS (Transduction laboratories, Lexington, KY) [13,15]. Other antibodies included a goat antibody against CD31 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a monoclonal antibody against β-actin (Sigma, St. Louis, MO, USA).

Immunoblotting analyses
SDS–PAGE and immunoblotting were performed as described [12,13,15]. Protein extracts from the visceral peritoneum were separated on 7.5% acrylamide slabs and transferred to nitrocellulose. Efficiency of transfer to nitrocellulose was tested by Ponceau red (Sigma) staining and immunoreactivity for β-actin. The membranes were blocked for 30 min, incubated overnight with the primary antibody at 4°C, washed, incubated for 1 h with peroxidase-labelled secondary antibodies (Dako, Glostrup, Denmark) and visualized with enhanced chemiluminescence (Amersham, Little Chalfont, UK). The immunoblots were performed at least in duplicate, and specificity of the signal was determined by comparison with positive controls. Densitometry analysis was performed with a StudioStar Scanner (Agfa-Gevaert, Mortsel, Belgium) using the NIH-Image V1-57 software.

Tissue staining and immunohistochemistry
Haematoxylin and eosin (HE) staining and immunostaining were performed as described previously [12,14,15]. After blocking in 0.3% H2O2 and incubation with 10% normal serum, sections were incubated for 45 min each with the primary antibody, biotinylated IgG and avidin–biotin peroxidase (Vector Laboratories, Burlingame, CA, USA). The MOM immunodetection kit (Vector) was used for monoclonal antibodies. Immunolabelling was visualized using aminoethylcarbazole (Vector). Sections were viewed under a Leica DMR coupled with a Leida DC 300 camera (Leica, Heerbrugg, Switzerland). The specificity of immunolabelling was confirmed by incubation without primary antibody and with nonimmune IgG (Dako). Microvascular density was assessed using CD31 immunostaining, as previously reported in detail [21]. Sections were digitalized to measure the density of vascular structures (in N vessels/mm2) and the relative endothelial area (i.e. the ratio between the cumulative endothelial area and the peritoneum area) as described [15,22]. All slides were coded and analysed by the same operator. The analysis included a mean of 10 fields per sample and four mice in each group. The intensity of the inflammatory reaction in the visceral peritoneum in four pairs of randomly selected iNOS mice was graded as follows: 0, absence of rolling; 1, rolling; 2, mild infiltrate (perivascular and/or interstitial); 3, severe infiltrate (perivascular and/or interstitial).

Determination of nitrite/nitrate (NOx)
The production of nitrite and nitrate in the dialysate was measured using a colorimetric assay based on the Griess reaction [15], following the manufacturer's instructions (Cayman Chemical, Ann Arbor, MI, USA).

Data analysis
Data are presented as mean ± SEM. Statistical analyses were performed using ANOVA and the appropriate parametric (Bonferroni) or non-parametric (Mann–Whitney) test for multiple comparisons (GraphPad Software, San Diego, CA, USA).



   Results
Top
 Abstract
 Introduction
 Material and methods
 Results
Discussion
 References
 
Effect of LPS on C57 BL/6J mice
Effect of LPS on NOx level in the dialysate: time-course analysis
Once released in biological fluids, NO is oxidized to the inactive and stable metabolites NO2/NO3 (NOx), which can be quantified as a surrogate marker of NO production [23]. Treatment with LPS induced a significant increase in the NOx level in dialysate (Figure 1). The induction was time dependent, reaching a maximum between 12 and 24 h, with a sharp decrease thereafter. Sequential analysis of the differential WBC count confirmed that this time course corresponded to a majority of macrophages (55 ± 2% at 12 h and 50 ± 3% at 18 h, N = 4 mice for each time-point) in the dialysate, before the characteristic neutrophil invasion was observed after 24 h (data not shown). Accordingly, most analyses were performed 18 h after LPS treatment.


Figure 1
View larger version (9K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Time course of dialysate NOx levels in LPS-treated mice. The total dialysate NOx (nitrate + nitrite) levels were measured using the Griess reaction. There were at least four mice at each time point. P < 0.001 (ANOVA); *P < 0.05 Tx versus T0.

 
Morphological characteristics of LPS-induced peritonitis
Morphological examination of the visceral and parietal peritoneum (HE staining) showed that, in comparison with control mice, LPS-induced acute peritonitis was reflected by a discrete infiltrate of inflammatory cells in both the visceral (Figure 2A,B) and parietal peritoneum (Figure 2C, D). The leukocytes infiltrate started at the early stage of inflammation. Six hours after LPS injection, the majority of inflammatory cells were polymorphonuclear leukocytes, mostly located in the capillary lumen. At 18 h, marginating leukocytes were observed in the capillaries (Figure 2E,F). There was no apparent difference in the nature of the leukocyte infiltrate between the three KO strains. After 48 h, the proportion of polymorphonuclear leukocytes decreased in parallel with a progressive increase in mononuclear leukocytes (macrophages and lymphocytes). At 120 h after LPS injection, there were clusters of mononuclear leukocytes (data not shown).


Figure 2
View larger version (131K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Effects of LPS-induced peritonitis on the peritoneum: morphology. Haemalun–eosine staining in the visceral (A, B, E and F) and parietal (C and D) peritoneum of control (A, C and E) or LPS-treated mice (B, D and F). LPS-induced peritonitis is reflected by an inflammatory infiltrate in the visceral (B) and parietal (D) peritoneum. Marginating and perivascular leukocytes are clearly identified in LPS-treated mice (F).

 
Effect of LPS-induced peritonitis on NOS expression
Immunostaining (Figure 3) showed that LPS-induced acute peritonitis was associated with the increased eNOS signal in the endothelium lining peritoneal blood vessels (Figure 3A,B) and increased immunoreactivity for nNOS in endothelial and perivascular inflammatory cells including macrophages, and nerve sections (Figure 3C–F). The LPS treatment was also reflected by the induction of iNOS immunoreactivity in rare, infiltrating macrophages (data not shown). Morphometry analysis on CD31-stained sections confirmed that both the vascular density (in vessels/mm2: 58 ± 10 in control mice versus 85 ± 16 in LPS-treated mice, P = 0.22) and cumulative endothelial area (1.1 ± 0.4% in control mice versus 1.6 ± 0.3% in LPS-treated mice, P = 0.33) were not significantly modified 18 h after LPS treatment. Immunoblotting studies (Figure 4) demonstrated that LPS-induced peritonitis was associated with a major upregulation of nNOS (155 kD) and eNOS (140 kD), and the induction of iNOS (130 kD) in the peritoneum (Figure 4A). Densitometry analysis confirmed that LPS treatment induced an 11-fold increase in nNOS expression (relative optical density: 1170 ± 200%, P = 0.005), and 2-fold increase in eNOS expression (relative optical density: 247 ± 110%, P = 0.01) in the peritoneum (Figure 4B).


Figure 3
View larger version (132K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 LPS induction of eNOS and nNOS in the peritoneum: immunostaining. Immunostaining for eNOS (A and B) and nNOS (C–F) in the visceral peritoneum of control (A, C and E) and LPS-treated mice (B, D and F). Immunoreactivity for eNOS is located in the endothelium lining peritoneal blood vessels in control mice (A). The staining intensity of blood vessels stained for eNOS is markedly increased in LPS-treated mice with peritonitis (B). Immunoreactivity for nNOS is located in the scattered nuclei of visceral peritoneum in control mice (C) and is over-expressed in endothelial cells, nerve sections and perivascular inflammatory cells (D and F) in LPS-induced peritonitis.

 

Figure 4
View larger version (25K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 4 LPS induction of NOS isoforms: immunoblotting. Representative immunoblots for nNOS, eNOS and iNOS in peritoneum extracts prepared from control mice and LPS-treated mice (20 µg protein/lane). The blots were stripped and reprobed for β-actin for loading accuracy. A consistent upregulation of nNOS (155 kD) and eNOS (140 kD) is detected in LPS-treated mice. The signal for iNOS (130 kD, lower band of the blot) is not detected in control samples but appears in LPS-treated mice. Densitometry analysis confirms the major upregulation of nNOS (relative optical density: 1170 ± 200%, *P = 0.005) and eNOS (relative optical density : 247 ± 110%, *P = 0.01) following LPS.

 
Effect of LPS on mice lacking specific NOS isoforms
Clinical and biological parameters
All mice used in the study were similar in terms of body weight and haematocrit (Table 1). Mice lacking eNOS, which have a higher mean arterial blood pressure (MAP) at baseline [15,17], showed a trend for higher MAP during acute peritonitis (Table 1). In comparison with control mice, mice with LPS-induced peritonitis were characterized by cloudy dialysates and significantly increased WBC counts. Among the LPS-treated mice, mice lacking iNOS showed significantly higher WBC counts in the dialysate versus their wild-type littermates (Table 1). Further examination of the visceral peritoneum (Figure 5) revealed that the extent of inflammation induced by LPS was significantly higher in iNOS KO versus WT mice (inflammation score: 2.3 ± 0.3 versus 0.8 ± 0.2, N = 5, P < 0.01). These modifications were not observed in the eNOS and nNOS mice. The iNOS KO mice were also characterized by a higher mortality rate following LPS injection (mortality rate: 1/6 in iNOS WT versus 4/10 in iNOS KO mice).


View this table:
[in this window]
[in a new window]

  		Table 1 Clinical and biological parameters in the NOS isoform mice

 

Figure 5
View larger version (67K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 5 Peritoneal infiltrate in iNOS mice. Haemalun–eosine staining in the visceral peritoneum (A) of LPS-treated iNOS WT mice (upper panel) and iNOS KO mice (lower panel). LPS-induced peritonitis is reflected by a discrete inflammatory infiltrate, which is markedly more severe in iNOS KO mice. The infiltrate score (B) is significantly increased in LPS-treated iNOS KO mice (P < 0.01 versus iNOS WT mice, n = 6).

 
Transport parameters in mice: effects of specific NOS deletion
The effects of LPS-induced peritonitis on transport parameters were investigated in NOS KO mice, using a 2-h PD exchange (Figures 6–8GoGo, Table 2). This protocol induced a progressive increase in the dialysate-to-plasma ratio for urea (panel A), a progressive reabsorption of glucose from the dialysate (panel B), a fall in the dialysate-to-plasma ratio of sodium during the first 30 min of the dwell (sodium sieving; panel C) and a net UF (panel D) as previously reported [20]. Acute peritonitis induced by LPS caused a major increase in the small solute transport (urea and glucose), with a loss of sodium sieving and a loss of UF in WT-LPS mice. All these modifications were significantly attenuated in eNOS KO mice, with a partial recovery of sodium sieving and UF, and a reduced transport for small solutes (Figure 6, Table 2). In strong contrast, the LPS-induced transport modifications were not significantly modified in mice lacking iNOS (Figure 7) or nNOS (Figure 8) (see also Table 2).


Figure 6
View larger version (20K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 6 PD transport parameters: effect of LPS and eNOS deletion. The dialysate-to-plasma (D/P) ratio of urea (panel A) and sodium (panel C), the progressive removal of glucose from the dialysate (D/D0 glucose; panel B) and net ultrafiltration (UF normalized to BW, panel D) were determined in control mice (WT, open squares), eNOS WT mice treated with LPS (WT-LPS, black squares) and eNOS KO mice with LPS (KO-LPS, black triangles) during a 2-h exchange. LPS treatment induces a major increase in the transport of urea and glucose, with a loss of sodium sieving and a loss of ultrafiltration. All these modifications are significantly attenuated in eNOS KO mice. *P < 0.05 versus WT mice; #P < 0.05 versus eNOS WT-LPS mice.

 

Figure 7
View larger version (19K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 7 PD transport parameters: effect of LPS and iNOS deletion. The dialysate-to-plasma (D/P) ratio of urea (A) and sodium (C), the progressive removal of glucose from the dialysate (D/D0 glucose, B) and net ultrafiltration (UF/BW, D) were determined in control mice (WT, open squares), iNOS WT mice treated with LPS (WT-LPS, black squares) and iNOS KO mice treated with LPS (KO-LPS, black triangles) during a 2-h exchange. Acute peritonitis induces a major increase in the urea and glucose transport, with a loss of sodium sieving and a loss of ultrafiltration. These changes are not modified in iNOS KO mice. *P < 0.05 versus WT mice.

 

Figure 8
View larger version (18K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 8 PD transport parameters: effect of LPS and nNOS deletion. The dialysate-to-plasma (D/P) ratio of urea (A) and sodium (C), the progressive removal of glucose from the dialysate (D/D0 glucose, B) and net ultrafiltration (UF/BW, D) were determined in control mice (WT, open squares), nNOS WT mice treated with LPS (WT-LPS, black squares) and nNOS KO mice with LPS (KO-LPS, black triangles) during a 2-h exchange. Acute peritonitis induces a major increase in the urea and glucose transport, with a loss of sodium sieving and a loss of ultrafiltration. These changes are not modified in nNOS KO mice. *P < 0.05 versus WT mice.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Water and solute transport across the peritoneum in NOS isoform mice

 
Effects of specific NOS deletion on dialysate NOx levels
Treatment with LPS induced a 15- to 30-fold increase in the dialysate NOx levels in all types of WT mice (Figure 9). The LPS-induced increase in NOx was significantly attenuated in eNOS KO mice (average: –50%) and almost abolished (average: –97%) in iNOS KO mice. These strong effects contrasted with a mild, non-significant decrease (average: –14%) in nNOS KO mice.


Figure 9
View larger version (15K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 9 Dialysate NOx levels: effect of eNOS, nNOS and iNOS deletion. Treatment with LPS in WT mice induced a significant increase in NO metabolites (NOx) in the dialysate. This effect was significantly reversed in eNOS KO mice (top panel) and almost abolished in iNOS KO mice (bottom panel), whereas it was unchanged in nNOS KO mice (middle panel). *P < 0.05 versus WT mice; #P < 0.05 versus WT-LPS mice. N = 4 in each group.

 


   Discussion
Top
 Abstract
 Introduction
 Material and methods
 Results
 Discussion
References
 
In the present study, we provide direct evidence suggesting that each NOS isoform plays a distinct role in the peritoneal membrane during acute peritonitis. These data are based on the differential expression of the NOS isoforms at baseline and during LPS-induced peritonitis, and on the characterization of clinical, biochemical, structural and transport parameters in wild-type mice versus mice lacking eNOS, iNOS and nNOS.

Several lines of evidence, obtained in rodent models and PD patients, show that the three NOS isoforms are differentially regulated according to the underlying pathogenic process [24]. A significant upregulation of eNOS alone has been documented in the peritoneal membrane exposed to long-term PD [25,26]. In contrast, catheter-induced peritonitis is reflected by a major increase in both eNOS and iNOS [12–15], whereas chronic uraemia induces changes in the expression of eNOS and nNOS [27]. The tightly regulated pattern of expression of NOS isoforms and the pleiotropic effects of NO raised the question of the role played by this complex system in the peritoneal membrane [28]. Using mouse models, we previously demonstrated the crucial role of eNOS in the structural modifications (infiltrate, vascular proliferation) and transport changes in acute peritonitis [15,20]. However, these data were obtained using a 6-day model of catheter-induced bacterial peritonitis in the single eNOS KO mouse. In contrast, the present study was designed to decipher the specific roles of the three NOS isoforms during the early phase of LPS-induced acute peritonitis.

Intraperitoneal administration of LPS, an integral component of the outer membrane of Gram-negative bacteria, initiates a rapid, coordinated recruitment and activation of leukocytes, followed by overproduction of proinflammatory mediators and NO [29]. Mice injected with LPS showed cloudy dialysates with increased WBC counts and NOx levels, inflammatory cell infiltrates in the peritoneum, a major upregulation of NOS and increased transport of small solutes with ensuing UF failure. These changes, which are similar to those documented in other models [12–16], are characteristic of acute peritonitis in PD patients [10,11]. The time of investigation, 18 h after LPS injection, corresponds to the maximal release of NO. Addition of the NOS inhibitor L-NAME at that time point significantly reversed transport modifications and NOx release in this model [16]. Taken together, these results suggested that the excessive release of NO may be involved in the early changes during peritonitis. However, because NOS inhibitors lack specificity, it has not been possible to characterize the role of each NOS isoform in this acute phase of inflammation/infection. Thus, transgenic mice lacking NOS isoforms provide an excellent tool to answer that question, using established procedures for investigation of the peritoneal membrane [20].

Endothelium-derived NO is a potent vasodilator that participates in the regulation of blood pressure, vascular permeability, angiogenesis and leukocyte adhesion [30–32]. We have shown previously that mice lacking eNOS are protected against functional and structural modifications in a 6-day model of peritonitis [15]. The present data confirm and extend these findings, by showing that the lack of eNOS significantly attenuates the acute increase in the small solute transport induced by LPS, resulting in a significant improvement in UF. Of note, the deletion of eNOS does not totally reverse transport changes, as it does not abolish the burst of NOx release in the dialysate. This may be related to the uneven effect of LPS on the specific NOS regulation: the 2.5-fold increase in eNOS is below the induction of iNOS (normally absent from the peritoneum) and the >10-fold increase in nNOS. The lack of total reversibility could also be due to pro-inflammatory cytokines such as IL-6 liberated during inflammation [33] or, alternatively, to post-translational modifications of target proteins. At variance with the 6-day catheter peritonitis model, the upregulation of eNOS 18 h after LPS does not reflect a significant vascular proliferation in the peritoneum. This important difference illustrates the fact that eNOS, initially described as a constitutive isoform, can actually be induced by a variety of stimuli including growth factors, cytokines and bacterial LPS [2,34]. At any rate, the upregulation of eNOS is critical to regulate transport parameters in the early phase of peritonitis, which emphasizes the therapeutic potential of selective inhibitors targeting this isoform.

The induction of iNOS by cytokines and proinflammatory agents is known to increase NO production during many inflammatory responses, including peritonitis [12]. In particular, LPS bind to their CD14 receptor on the surface of macrophages, resulting in the transcriptional induction of iNOS with subsequent release of NO [35]. In turn, the generation of large quantities of NO by activated macrophages may contribute to circulatory failure and organ injury. However, enhanced NO release may also exert beneficial effects, including a bactericidal effect and augmentation of host defence [36,37]. Although it has been reported that iNOS-deficient mice exhibit enhanced leukocyte–endothelium interactions in endotoxaemia [38] and that iNOS activity plays a protective role in response to inflammation [39], the role of iNOS during acute peritonitis has not been addressed. The present study indicates that induction of iNOS in the peritoneal membrane is a major mechanism for the increased release of NO metabolites during the early phase of LPS peritonitis. Mice lacking iNOS showed a nearly complete abolition of NOx release in the dialysate despite unchanged transport parameters, which provides a strong argument for the local NO activity rather than increased transport from the circulation [11]. Of note, the abolition of NOx release may also reflect the fact that the exasperated inflammation due to the lack of iNOS may trigger the release of cytokines (including TNFalpha) down-regulating the expression of eNOS [40]. Furthermore, the lack of iNOS was reflected by higher WBC counts in the dialysate, more severe inflammatory changes in the tissue and a trend towards increased mortality following LPS treatment. Accordingly, it is tempting to propose that the release of NO meditated by iNOS exerts a protective role in acute peritonitis. This protective role may be related to host-defence mechanisms, independently of changes in transport parameters.

The nNOS isoform plays an important role in the generation of NO for neuronal development, maturation and neurotransmission [23,41]. nNOS is also expressed in extra-neuronal cells, including neutrophils [42], endothelial cells [43] and vascular smooth muscle cells [44]. In the peritoneum, nNOS is expressed in nerves and peritoneal arteries, where it could play a role in uraemic neuropathy and vasculopathy [27]. We demonstrate a 10-fold increase in nNOS expression in the peritoneum following LPS. Like eNOS, the expression of the ‘constitutive’ nNOS can be regulated in response of neuronal cells to stress [2]. The strong induction observed here appears to be related either to the time course or the nature of the stimulus. Indeed, the 6-day model of catheter-induced peritonitis does not induce nNOS expression [12] whereas LPS treatment induces nNOS expression in muscles [45]. The role of nNOS in the peritoneum is distinct from that of eNOS and iNOS, with a minimal effect on NOx release, and no reversibility on transport parameters. These differences may reflect expression in distinct cellular compartments. Alternatively, one could hypothesize that the deletion of nNOS may induce compensatory upregulation of other NOS isoforms in the peritoneal membrane [46]. A trend for increased dialysate WBC counts was observed in nNOS KO mice, supporting the hypothesis that nNOS deficiency may promote leukocyte rolling and adhesion [47]. However, at variance with iNOS, this was not reflected by changes in the severity of inflammatory reaction to LPS. By analogy with other models, one could hypothesize that nNOS may regulate inflammatory pain [48] during acute peritonitis.

In summary, we have shown that the LPS-induced acute peritonitis in the mouse is reflected by the upregulation of the three NOS isoforms. The transport alterations induced by peritonitis were reversed in eNOS KO mice, whereas the inflammatory changes were more severe in iNOS KO mice. These data give new insights in the differential roles of NOS isoforms in the peritoneal membrane and suggest that selective eNOS inhibition may improve peritoneal transport during acute peritonitis, whereas non-specific NOS inhibitors may impair host-defence mechanisms [49,50].



   Acknowledgments
 
These studies were supported in part by the Belgian agencies FNRS and FRSM (3.4.592.06F), a Concerted Research Action (05/10-328), an Inter-university Attraction Pole (IUAP P6/05) and grants from Baxter Belgium. We are very grateful to E. Goffin, R. Krediet, N. Lameire, B. Lindholm and B. Rippe for providing invaluable suggestions and critiques. The expert technical assistance of A. Saliez and L. Wenderickx is highly appreciated.

Conflict of interest statement. None declared.



   References
Top
 Abstract
 Introduction
 Material and methods
 Results
 Discussion
 References
 

  1. Asano K, Chee CB, Gaston B, et al. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci USA (1994) 91:10089–10093.[Abstract/Free Full Text]
  2. Forstermann U, Boissel JP, Kleinert H. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J (1998) 12:773–790.[Abstract/Free Full Text]
  3. Nakane M, Schmidt HH, Pollock JS, et al. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett (1993) 316:175–180.[CrossRef][Web of Science][Medline]
  4. Wallerath T, Gath I, Aulitzky WE, et al. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost (1997) 77:163–167.[Web of Science][Medline]
  5. Reiling N, Kroncke R, Ulmer AJ, et al. Nitric oxide synthase: expression of the endothelial, Ca2+/calmodulin-dependent isoform in human B and T lymphocytes. Eur J Immunol (1996) 26:511–516.[Web of Science][Medline]
  6. Shaul PW, North AJ, Wu LC, et al. Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium. J Clin Invest (1994) 94:2231–2236.[Web of Science][Medline]
  7. Xue C, Pollock J, Schmidt HH, et al. Expression of nitric oxide synthase immunoreactivity by interstitial cells of the canine proximal colon. J Auton Nerv Syst (1994) 49:1–14.[CrossRef][Web of Science][Medline]
  8. Connelly L, Jacobs AT, Palacios-Callender M, et al. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem (2003) 278:6480–6487.
  9. Gokal R. Peritoneal dialysis in the 21st century: an analysis of current problems and future developments. J Am Soc Nephrol (2002) 13(Suppl_1):S104–S116.[Free Full Text]
  10. Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, et al. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest (1987) 17:43–52.[Web of Science][Medline]
  11. Douma CE, de Waart DR, Struijk DG, et al. Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis ? J Lab Clin Med (1998) 132:329–340.[CrossRef][Web of Science][Medline]
  12. Combet S, Van Landschoot M, Moulin P, et al. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol (1999) 10:2185–2196.[Abstract/Free Full Text]
  13. Combet S, Balligand JL, Lameire N, et al. A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney Int (2000) 57:332–338.[CrossRef][Web of Science][Medline]
  14. Ferrier ML, Combet S, van Landschoot M, et al. Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int (2001) 60:2343–2350.[CrossRef][Web of Science][Medline]
  15. Ni J, Moulin P, Gianello P, et al. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol (2003) 14:3205–3216.[Abstract/Free Full Text]
  16. Ni J, Cnops Y, McLoughlin RM, et al. Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int (2005) 25:S11–S14.[Abstract/Free Full Text]
  17. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA (1996) 93:13176–13181.[Abstract/Free Full Text]
  18. Wei XQ, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 375:408–411.[CrossRef][Medline]
  19. Huang PL, Dawson TM, Bredt DS, et al. Targeted disruption of the neuronal nitric oxide synthase gene. Cell (1993) 75:1273–1286.[CrossRef][Web of Science][Medline]
  20. Ni J, Cnops Y, Debaix H, et al. Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int (2005) 67:2021–2031.[CrossRef][Web of Science][Medline]
  21. Chantrain CF, DeClerck YA, Groshen S, et al. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem (2003) 51:151–158.[Abstract/Free Full Text]
  22. Ismail JA, Poppa V, Kemper LE, et al. Immunohistologic labeling of murine endothelium. Cardiovasc Pathol (2003) 12:82–90.[CrossRef][Web of Science][Medline]
  23. Moncada S, Palmer M, Higgs E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev (1991) 43:109–142.[Web of Science][Medline]
  24. Devuyst O, Combet S, Cnops Y, et al. Regulation of NO synthase isoforms in the peritoneum: implications for ultrafiltration failure in peritoneal dialysis. Nephrol Dial Transplant (2001) 16:675–678.[Abstract/Free Full Text]
  25. Goffin E, Combet S, Jamar F, et al. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport. Am J Kidney Dis (1999) 33:383–388.[Web of Science][Medline]
  26. Combet S, Miyata T, Moulin P, et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol (2000) 11:717–728.[Abstract/Free Full Text]
  27. Combet S, Ferrier ML, Van Landschoot M, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol (2001) 12:2146–2157.[Abstract/Free Full Text]
  28. Miyata T, Devuyst O, Kurokawa K, et al. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int (2002) 61:375–386.[CrossRef][Web of Science][Medline]
  29. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 338:436–445.[Free Full Text]
  30. Gaboury J, Woodman RC, Granger DN, et al. Nitric oxide prevents leukocyte adherence: role of superoxide. Am J Physiol (1993) 265:H862–H867.[Web of Science][Medline]
  31. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA (1991) 88:4651–4655.[Abstract/Free Full Text]
  32. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol (1992) 262:H611–H615.[Web of Science][Medline]
  33. Topley N, Liberek T, Davenport A, et al. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int Suppl (1996) 56:S17–S21.[Medline]
  34. Cirino G, Fiorucci S, Sessa WC. Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci (2003) 2:91–95.
  35. Thiemermann C. Nitric oxide and septic shock. Gen Pharmacol (1997) 2:159–166.
  36. Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol (1991) 1:65–70.
  37. Szabo C, Thiemermann C. Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol (1995) 34:113–153.[CrossRef][Medline]
  38. Hickey MJ, Sharkey KA, Sihota EG, et al. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J (1997) 11:955–964.[Abstract]
  39. McCafferty DM, Mudgett JS, Swain MG, et al. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology (1997) 112:1022–1027.[CrossRef][Web of Science][Medline]
  40. Yan G, You B, Chen SP, et al. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res (2008) 103:591–597.[Abstract/Free Full Text]
  41. Michel T, Feron O. Perspective series: nitric oxide synthases. J Clin Invest (1997) 100:2146–2152.[Web of Science][Medline]
  42. Wallerath T, Gath I, Aulitzky WE, et al. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost (1997) 77:163–167.[Web of Science][Medline]
  43. Bachetti T, Comini L, Curello S, et al. Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. J Mol Cell Cardiol (2004) 37:939–945.[CrossRef][Web of Science][Medline]
  44. Schwarz PM, Kleinert H, Forstermann U. Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol (1999) 19:2584–2590.[Abstract/Free Full Text]
  45. Comtois AS, Barreiro E, Huang PL, et al. Lipopolysaccharide-induced diaphragmatic contractile dysfunction and sarcolemmal injury in mice lacking the neuronal nitric oxide synthase. Am J Respir Crit Care Med (2001) 163:977–982.[Abstract/Free Full Text]
  46. Ortiz PA, Garvin JL. Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol (2003) 284:R628–R638.[Abstract/Free Full Text]
  47. Lefer DJ, Jones SP, Girod WG, et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol (1999) 276:H1943–H1950.[Web of Science][Medline]
  48. Tao F, Tao YX, Zhao C, et al. Differential roles of neuronal and endothelial nitric oxide synthases during carrageenan-induced inflammatory hyperalgesia. Neuroscience (2004) 128:421–430.[CrossRef][Web of Science][Medline]
  49. Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase—time for reappraisal. Curr Drug Targets Inflamm Allergy (2002) 1:89–108.[CrossRef][Medline]
  50. Paige JS, Jaffrey SR. Pharmacologic manipulation of nitric oxide signalling: targeting NOS dimerization and protein-protein interactions. Curr Top Med Chem (2007) 7:97–114.[CrossRef][Web of Science][Medline]
Received for publication: 7. 4.09
Accepted in revised form: 23. 7.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ni, J.
Right arrow Articles by Devuyst, O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ni, J.
Right arrow Articles by Devuyst, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?